chrisvoncsefalvay/vaers-outcomes huggingface dataset:
feeling weak; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (feeling weak) in a 41-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     The patient's past medical history included COVID-19.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Mar-2021, the patient experienced ASTHENIA (feeling weak). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form, qd. At the time of the report, ASTHENIA (feeling weak) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported.   Reporter did not allow further contact
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. During 2012, the patient was vaccinated with ZOSTAVAX, (lot# and route unknown) as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. In 2016, the patient was treated at a medical center, for the onset of a vesicular rash, which was diagnosed as severe herpes zoster, or shingles. As a direct and proximate result of the ZOSTAVAX vaccine and/or despite receiving ZOSTAVAX, for long-term prevention of shingles, the patient suffered painful injuries and damages and required extensive medical care and treatment.  As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
On 11/1/00, child had a fever spike at 104F, post vax. He had two 5 minute seizures.
Day of vaccine a few hours later I had a migrane start to form and I felt off. Sunday morning the migrane had ebbed a bit until about 12 noon. By that point I was in bed almost all day with muscle pain in my torso (back, ribs, abdominal). I also had a severe migrane and a fever that at it's worst was 102.3. It was brought down quickly with ice to 100.7 within an hour. After about 8 hours it subsided for about 20 minutes before the torso pain and migrane came back. The fever stayed around 100.3 when I last checked. I went back to sleep for the rest of the night and felt fine in the morning with no fever.
Patient developed shingles all over her body; This case was reported by a other health professional via call center representative and described the occurrence of shingles in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 2 days after receiving Shingrix, the patient experienced shingles. Shingrix was discontinued. On an unknown date, the outcome of the shingles was recovered/resolved.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received the vaccination at a different location so the reporter had limited information. The patient developed shingles all over her body about 2 days after receiving Shingix. She has elected not to receive the 2nd dose.The visit to this doctor was not related to Shingles.
her temperature started spiking she had 105 temperature; high blood pressure; she had some bacteria in her blood; she got really sick; This is a spontaneous report from a contactable consumer. This consumer reporter a female patient of unspecified age that who received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 11Mar2021 at single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. Consumer stated that his wife had the COVID shot last week Thursday and she wasn't running and tempura or anything like that. Than all of a sudden Friday she got really sick on 12Mar2021. Then she stopped a Pharmacy cause they have a little Doctor station there. All of a sudden her temperature started spiking she had 105 temperature and high blood pressure, had to take her immediately to the hospital with an ambulance. She tested negative for COVID-19. They found out she had some bacteria in her blood. Outcome of the events was unknown.   Information on the lot/batch number has been requested.
Patient arrived at facility for dose No. 2 of Moderna.  Patient is 17 years old and therefore unable to receive vaccination.  Vaccine not given today.
Patient lost feeling in right arm for 10 minutes. Regained full feeling after 30 minutes per patient.
Patient received a dose of COVID vaccine MODERNA on 12/31/20 at Medical Center facility.  9 days later on 1/8/2021 patient received a dose of COVID vaccine.  At that time, patient did not disclose he had a previous dose of COVID vaccine. at another facility.  Pt received on 1/8/21 Lot # EL0142  Intramuscular in Left deltoid.
lot of hair loss after 16Apr2022 shot; BNT162B2 dose 1: 13Mar2021, dose 2: 16Apr2022 shot; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), on 16Apr2022 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: comirnaty (DOSE 1, SINGLE), administration date: 13Mar2021, for COVID-19 immunization, reaction(s): "hair in my sink". The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 16Apr2022, outcome "unknown", described as "BNT162B2 dose 1: 13Mar2021, dose 2: 16Apr2022 shot"; ALOPECIA (non-serious), outcome "unknown", described as "lot of hair loss after 16Apr2022 shot". Therapeutic measures were taken as a result of alopecia.  Additional information: The patient had platelet-rich plasma (PRP) blood platelet treatments in Feb2023 for the hairloss.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300104044 same patient, product and event; different dose;US-PFIZER INC-202300219429 same patient, product and event; different dose;
System pain in upper legs; stiffness; bp raised; Cannot touch the body; increased blood sugar level; severe Joint pain; system pain in hips; Chills; Fever; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (System pain in upper legs), MUSCULOSKELETAL STIFFNESS (stiffness), BLOOD PRESSURE INCREASED (bp raised), PAIN (Cannot touch the body) and BLOOD GLUCOSE INCREASED (increased blood sugar level) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 100a21a) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (System pain in upper legs), MUSCULOSKELETAL STIFFNESS (stiffness), BLOOD PRESSURE INCREASED (bp raised), PAIN (Cannot touch the body), BLOOD GLUCOSE INCREASED (increased blood sugar level), PYREXIA (Fever), CHILLS (Chills) and ARTHRALGIA (system pain in hips). an unknown date, the patient experienced ARTHRALGIA (severe Joint pain). At the time of the report, PAIN IN EXTREMITY (System pain in upper legs), MUSCULOSKELETAL STIFFNESS (stiffness), BLOOD PRESSURE INCREASED (bp raised), PAIN (Cannot touch the body), BLOOD GLUCOSE INCREASED (increased blood sugar level), PYREXIA (Fever), ARTHRALGIA (severe Joint pain), CHILLS (Chills) and ARTHRALGIA (system pain in hips) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Treatment for the events include anti-inflammatory and pain medication   Most recent FOLLOW-UP information incorporated above includes: On 24-May-2021: TCR received on 24-MAY-2021, in which new Adverse events and Reporters email address updated
two weeks after my third shot, the tinnitus symptoms (pretty severe--mainly plugged up right ear) reappeared; third shot; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 51 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 18Nov2021 17:00 (Batch/Lot number: unknown) at the age of 50 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: Bnt162b2 (Prev dose vaccine location=Left arm, Prev dose product=COVID 19, Prev dose brand unknown=True, Prev dose brand name unknown=COVID19 Vaccine, Prev dose lot unknown=True, Prev dose lot unknown reason=Unable to locate or read the details, Prev dose administration date=16Mar2021, Prev dose administration time=08:15AM, Prev dose dose number=1), administration date: 16Mar2021, when the patient was 50 years old, for Covid-19 Immunization; Bnt162b2 (Prev dose product=COVID 19, Prev dose brand unknown=True, Prev dose brand name unknown=COVID19 Vaccine, Prev dose lot unknown=True, Prev dose lot unknown reason=Unable to locate or read the details, Prev dose administration date=06Apr2021, Prev dose administration time=08:15AM, Prev dose dose number=2), administration date: 06Apr2021, when the patient was 50 years old, for COVID-19 immunization, reaction(s): "tinnitus". The following information was reported: IMMUNISATION (non-serious) with onset 18Nov2021 17:00, outcome "unknown", described as "third shot"; TINNITUS (non-serious) with onset 02Dec2021 07:00, outcome "not recovered", described as "two weeks after my third shot, the tinnitus symptoms (pretty severe--mainly plugged up right ear) reappeared". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of tinnitus.  Additional information: Facility type vaccine: Pharmacy or Drug Store, No other vaccine in four weeks, No Other medications in two weeks. I started experiencing tinnitus shortly after my second dose in April. After six months, the symptoms started to disappear. Then right at two weeks after my third shot, the tinnitus symptoms (pretty severe-mainly plugged up right ear) reappeared. I do not know for sure if the vaccinations caused the tinnitus, but it is very coincidental that it would flare up right after two weeks from the second and 3rd shots. However, I am so grateful for the vaccine and really appreciate what Pfizer has done to help out humanity! Thank you so much. Just wanted you to know that it may have caused a side-effect for me. No covid prior vaccination. Tested for covid post vaccination. No known allergies.  The lot number for bnt162b2 was not provided and will be requested during follow up.
A non-serious spontaneous report of administration of expired FLUMIST was received from a health professional concerning a four-year-old male, subsequent to FLUMIST. This case will be submitted in accordance with MedImmune's FLUMIST post-marketing commitment for the indicated population of 2 years to 59 months of age. The patient's medical history included ear infection. Concomitant medications included amoxicillin for ear infection. The patient received FLUMIST on 17-Jan-2012. On 26-Jan-2012, the patient experienced rash. The outcome of the events administration of expired FLUMIST and rash was recovered. Additional information was received on 04-Apr-2012 and incorporated into the narrative: an adverse event, medical history and concomitant medication. Additional information was obtained on 25-Apr-2012 and incorporated in the narrative: event information.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 64 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administration date 16Aug2021 (Batch/Lot number: unknown) at the age of 64 years as dose 3 (booster), single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 2, Single, Manufacturer unknown, Lot unknown/Not available), administration date: 06Apr2021, when the patient was 63 years old, for Covid-19 immunization; Covid-19 vaccine (Dose 1, Single, Manufacturer unknown, Lot unknown/Not available), administration date: 16Mar2021, when the patient was 63 years old, for Covid-19 immunization. The following information was reported: FRACTURE (medically significant), outcome "recovered with sequelae", described as "I got an MRI and that showed thousands of little fractures"; ARTHRALGIA (non-serious), JOINT SWELLING (non-serious) all with onset Aug2021, outcome "recovered with sequelae" and all described as "3 days after the third shot, I had pain and swelling in both ankles."; GAIT DISTURBANCE (non-serious), outcome "recovered with sequelae", described as "Could not walk"; FALL (non-serious), outcome "recovered with sequelae", described as "and fell". The events "I got an MRI and that showed thousands of little fractures", "3 days after the third shot, I had pain and swelling in both ankles", "3 days after the third shot, I had pain and swelling in both ankles", "could not walk" and "and fell." Was evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: magnetic resonance imaging: showed thousands of little fractures. Clinical Information: Patient did not received Covid prior vaccination. It is unknown, if patient Covid tested post vaccination. Patient was recovered with lasting effects. The lot number for bnt162b2 was not provided and will be requested during follow up.
44 yo male pt c/o a rash post vaccination. The rash is localized to the vaccination site in patients right deltoid region. It is approximately one inch in size, non pruritus, erythematous, and circular with a symmetric border. Patient states that this reaction has never occurred with any previous vaccine. Pt denies SOB, CP, or headache. Pt was given 25mg Benadryl and water. Vitals were stable for patient to leave the observation site. Patient was advised to f/u with PCP. BP- Machine error (pt BP usually low normal) HR- 93 (considering anxiety from vaccination experience) SpO2 96%
Information has been received from a medical assistant concerning a 19 year old female with penicillin allergy who on 10-JUL-2007 was vaccinated intramuscularly with a 0.5 ml first dose of GARDASIL (Lot # 658100/0525U). There was no concomitant medication. On 10-JUL-2007 several hours later the patient developed vomiting and diarrhea. The patient contacted the office by phone but no therapy was required. On 10-JUL-2007 the vomiting and diarrhea resolved after a few hours and the patient completely recovered. Additional information has been requested. This is in follow-up to report (s) previously submitted on 10/12/2007. Information has been received from a medical assisitant concerning a 19 year old female (151 lbs, 63 in,) with penicillin allergy who on 10-JUL-2007 was vaccinated intramuscularly with a 0.5 ml first dose of HPV vaccine (Lot #655100/0525U). There was no concomitant medication. On 10-JUL-2007 several hours later the patient developed vomiting and diarrhea. The patient contacted the office by phone but no therapy was required. On 10-JUL-2007 the vomiting and diarrhea resolved after a few hours and the patient completely recovered. The patient refused further vaccinations with HPV vaccines. No further information is available.
administered 2nd dose of shingrix  in 2.5 week from the first dose; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 60-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included RECOMBINANT VARICELLA ZOSTER VIRUS SURFACE GLYCOPROTEIN E (SHINGRIX).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.   Additional Information: GSK Receipt Date: 10-MAY-2022 Reporters comment: Pharmacist reported that, the patient was administered 2nd dose of Shingrix in 2.5 week from the first dose for immunocompetent patient. Consent of follow up was not asked since healthcare professional released the call before having the opportunity to be asked for.  Healthcare professional did not provide any other detail.  Additional supportive information: The patient received 2nd dose of Shingrix, earlier than the recommended schedule, which led to shortening of vaccination schedule.
While showering 7AM Monday 9/2/19 morning, ankles were itching on left leg. Monday evening rash moved up. Tuesday spread to knee. Wednesday, spread to groin. Bumps blisters, very itchy. He has been using cortisone cream. Patient has dermatology appointment Monday.
Case received Pfizer covid vaccine for his first 2 doses from another provider.  He came to the public health covid clinic with his guardian and moderna vaccine was administered.  It was missed that he was less than 18 years old at the time the moderna vaccine was administered.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program. The reporter is the parent. A 33 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), when the patient was 33 years old, for COVID-19 immunization, reaction(s): "arm pain", "achy when lifting her arm". The following information was reported: DIARRHEA (non-serious), outcome "unknown", described as "diarrhea"; SLUGGISHNESS (non-serious), outcome "unknown", described as "sluggishness". Additional Information: Caller reports that her 33-year daughter received the COMIRNATY vaccine (does not know the date) and she experienced arm pain afterwards and it was "achy" when lifting her arm and after the second dose she reported having diarrhea after eating and sluggishness. The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up. Follow-up (11Oct2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.
Pt experienced pain upon injection. Has been sore since and not gotten any better. Can barely use arm. Multiple visit to MD. Now has appt. w/orthopedic doctor. Pt undergoing physical therapy.
Dating Summary  Working EDD: 09/14/21 on 02/26/21 based on Last Menstrual Period on 12/08/20 Last Menstrual Period on 12/08/20 09/14/21 Working  LPN 02/26/21 Ultrasound on 02/26/21 09/15/21 LPN 02/26/21   Progress Notes. Obstetrics and Gynecology COVID Positive on pre-admission screen.  Asymptomatic. Temp 98.9:  O2 sat of 99% UNSCHEDULED visit for evaluation of Vaginal discharge Speculum exam reveals a small amount of blood tinged mucoid discharge > nitroarene positive.  Negative pooling Last coitus five days ago. Negative for ferning.  Cervix 1/ 60% / Vtx Instructed pati
Came in for second vaccine and indicated on screening possible reaction to first vaccine.   Mom stated this occurred that evening while watching TV.  Patient stated she had some swelling in throat, face and some difficulty breathing that was relieved with benadryl.
DDX reaction to the pertussis in DTAP #5. Became pale approx 15-30 minutes after imm in peds. Returned to peds at Dr.'s direction. Place on exam table with head of the table raised slightly and head at the foot of the table. BP initially 76/50 and 15 min later 72/50 both recumbent; soon after 2nd BP stood up and BP 78/50; initial pulse 84 and final pulse 72. Pale at first and good color at end. Ultimately able to walk up and down the hall x3: felt fine. Went home and slept the entire afternoon. As of 9 PM up and fine. No vom or loss of consciousness throughout.
At 8:15 second hepatitis B injection given. Child left clinic with no problem. 10 AM, mom called saying at 9:45 he had eaten 4 pieces of chocolate candy and now had "hives on neck and chest. No difficulty breathing or swallowing. At 10:30 child was taken back to clinic. Had flat red rash on neck, cheeks, upper back, chest and upper part of both arms. Rash is itchy. Patient evaluated, rash resolved.
At baseline, patient was a crossfit athlete. He presented in cardiogenic shock from presumed myocarditis. He is now s/p LVAD.
Information has been received from a physician concerning a female who approximately 2 months ago in March 2008, was vaccinated PO with her first dose of ROTATEQ (lot# not provided). A couple of days after vaccination, the baby experienced vomiting and diarrhea. The patient sought unspecified medical attention. No labs or diagnostic studies were performed. Subsequently, the patient recovered. No additional information was provided. there was no product quality complaint. Additional information has been requested. Follow-up information from the reporting physician indicated that an 8 week old female who on 31-MAR-2008 at 08:00 was vaccinated PO with her first dose of ROTATEQ (lot# 659918/0141X). There was no illness at the time of vaccination. On the same day at 20:00, the patient experienced vomiting and loose watery stools. Subsequently, the patient recovered from vomiting and diarrhea, several loose watery stools. No medical atention was sought. No intraveneous or medial intervention was necessary. The patient recovered spontanwously on 03-APR-2008. Additional information has been requested.